Device hybrid approval not the same as substance authorisation, rules CJEU
In a decision that will disappoint medical device manufacturers, the CJEU in the Boston Scientific case has addressed the authorisation that must form the basis of an SPC. This is in contrast to recent referrals that address what products can be protected
In a new supplementary protection certificate (SPC) development, the CJEU has ruled that the authorisation procedure for a pharmaceutical medical-device hybrid cannot be treated as an authorisation procedure for the substance.
In its judgment on the Boston Scientific case (C-527/17),...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.